Asthma
Conditions
Brief summary
To compare the bronchodilator efficacy of ipratropium plus salbutamol (Combivent) with salbutamol alone given every 20 minutes for three doses in asthmatic children with severe acute exacerbation
Detailed description
A Comparison of Ipratropium 500mcg and salbutamol 2.5mg (Combivent UDV) and salbutamol UDV alone (2.5mg) in a Double-blind, Efficacy and Safety Study in Asthmatic Children with Severe Acute Exacerbation Study Hypothesis: Several studies, including a study conducted in an emergency room setting, demonstrated that the addition of ipratropium bromide, an anticholinergic drug, to standard salbutamol therapy significantly improves pulmonary function as compared to salbutamol alone. Comparison(s): Ipratropium bromide 500 mcg plus salbutamol 2.5mg (Combivent) vs salbutamol (2.5mg) alone given every 20 minutes for 3 doses
Interventions
DRUGipratropium plus salbutamol UDV
DRUGsalbutamol UDV
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
2 Years to 10 Years
Healthy volunteers
No
Inclusion criteria
1. All patients must have a known history of asthma and present to the hospital/clinic with severe acute exacerbation. 2. Male or female patients 2 to 10 years of age. 3. Parents or legal guardians of patients must sign an Informed Consent Form prior to participation in the trial.
Exclusion criteria
1. Patients with known or suspected hypersensitivity to study drugs 2. Patients with medical condition that would contraindicate the use of beta2-adrenergic or anticholinergic medications 3. Patients with first wheezing episode only 4. Prior intubation for asthma for more than 24 hours 5. Patients who used ipratropium within six hours prior to consultation 6. Patients with concurrent stridor or possible presence of intra-thoracic foreign body 7. Patients with disease known to have chronic effect on respiratory function ( e.g., cystic fibrosis or cardiac disease) 8. Patients requiring immediate resuscitation or airway intervention 9. With psychiatric disease or psychosocial problems 10. Patients on other investigational drugs or have used any other investigational drugs within the past month
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients showing improvement in asthma severity scores from severe at baseline to mild at the end of the treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in asthma severity scores from baseline to end of treatment; number of patients needing hospitalization; number of rescue medications; oxygen saturation, number of discharged patients revisiting the ER/doctors clinic | — |
Countries
Philippines
Outcome results
None listed